Skip to main content

Table 1 Baseline characteristics of study population in the CREDIT registry

From: Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis

 

Total cohort

Without comorbidity

With comorbidity

Any

CVD

Fracture

Malignancy

N (%)

13,210 (100)

12,651 (95.8)

559 (4.2)

293 (2.2)

222 (1.7)

78 (0.6)

Demographic features

 Female, %

80.6

80.8

77.6

68.6

88.3

80.8

 Age, ya

52.9 ± 13.1

52.4 ± 13.0

62.9 ± 10.8

65.6 ± 9.5

61.0 ± 11.8

60.9 ± 10.4

 Age ≥ 60, %

32.7

31.2

66.9

75.4

61.7

59.0

Clinical characteristics

 RA duration, yb

4.0 (1.3–10.0)

4.0 (1.2–10.0)

6.3 (2.0–13.1)

6.0 (1.4–12.9)

7.7 (3.0–15.7)

4.0 (1.2–10.7)

 RF/CCP+, %

83.6

83.4

86.9

86.0

86.5

89.7

 ESR, mm/hb

34.0 (17.0–60.0)

33.0 (17.0–60.0)

41.0 (21.0–66.0)

40.0 (20.5–67.5)

39.5 (20.8–66.0)

45.0 (22.8–65.0)

 CRP, mg/Lb

10.3(3.2–30.0)

10.2 (3.2–30.0)

11.5 (3.2–35.8)

12.0 (3.3–39.2)

9.9 (3.2–35.5)

7.7 (2.8–29.7)

 DAS28-CRPa

4.5 ± 1.7

4.4 ± 1.7

4.7 ± 1.7

4.7 ± 1.7

4.7 ± 1.8

4.6 ± 1.8

Medications

 GC ever, %

40.6

40.5

43.1

46.1

41.9

34.6

 MTX ever, %

55.9

56.4

44.7

42.3

47.7

37.2

 bDMARDs, %

8.3

8.2

9.3

8.9

14.4

1.3

  1. CVD cardiovascular disease, RA rheumatoid arthritis, RF rheumatoid factor, CCP anti-citrullinated protein antibody, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate, CRP C-reactive protein, GC glucocorticoid, MTX methotrexate, bDMARDs biological disease-modifying antirheumatic drugs
  2. aData are presented as mean ± SD (standard deviation)
  3. bData are presented as median (IQR, interquartile range)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us